Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2009 - 2026)

Vanda Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $54.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 51.67% year-over-year to $54.0 million; the TTM figure through Mar 2026 stood at $54.0 million (down 51.67% YoY), while the FY2025 annual figure was $84.9 million, down 17.07% from the prior year.
• Cash & Equivalents came in at $54.0 million for Q1 2026 at Vanda Pharmaceuticals, down from $84.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $354.2 million in Q1 2023 to a low of $49.4 million in Q3 2022.
• A 5-year average of $115.6 million and a median of $102.3 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 429.19% in 2023 and tumbled 64.66% in 2024, its largest moves.
• Vanda Pharmaceuticals' Cash & Equivalents stood at $135.0 million in 2022, then climbed by 0.59% to $135.8 million in 2023, then fell by 24.67% to $102.3 million in 2024, then fell by 17.07% to $84.9 million in 2025, then tumbled by 36.32% to $54.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $54.0 million, $84.9 million, and $70.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison